Trial Profile
A Prospective Randomized Comparison of the BioFreedom Biolimus A9 Drug Coated Stent Versus the Gazelle Bare Metal Stent in Patients With High Risk of Bleeding
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 17 Aug 2020
Price :
$35
*
At a glance
- Drugs Umirolimus (Primary)
- Indications Acute coronary syndromes; Angina pectoris; Cardiovascular disorders; Coronary artery disease; Coronary artery restenosis
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms LEADERS FREE
- Sponsors Biosensors International Group
- 01 Jul 2020 Results of pre-specified analysis of LEADER-FREE trial published in the Revista Espanola de Cardiologia.
- 17 May 2016 Results of sub-study (n=659) published in the European Heart Journal
- 14 Oct 2015 Primary endpoint has been met. (Target vessel revascularisation event rate), as per an article published in the New England Journal of Medicine